Guo Rongqi, Wang Rui, Zhang Weisong, Li Yangyang, Wang Yihao, Wang Hao, Li Xia, Song Jianxiang
Department of Thoracic Surgery, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, 224000, People's Republic of China.
Medical School of Nantong University, Nantong, 226007, People's Republic of China.
Onco Targets Ther. 2024 Nov 12;17:977-989. doi: 10.2147/OTT.S496403. eCollection 2024.
Tumors, as chronic malignant diseases that account for about 20% of all deaths worldwide, are the number one threat to human health. Until now there is no reliable treatment for most types of tumors. Tumorigenesis and cellular carcinogenesis remain difficult challenges due to their complex etiology and unknown mechanisms. As stress process regulating molecules and protein folding promoters, heat shock proteins (HSPs) play an important role in cancer development. Most studies have shown that HSPs are one of the major anticancer drug targets. HSPs are not only modulators of the cellular stress response, but are also closely associated with tumor initiation, progression, and drug resistance, so understanding the mechanism of the HSP family involved in cellular carcinogenesis is an important part of understanding tumorigenesis and enabling anticancer drug development. In this review, we discuss the functions and mechanisms of key members of the HSP family (HSP70, HSP90, and HSP110) in participating in the process of tumorigenesis and cell carcinogenesis, and look forward to the prospect of key members of the HSP family in targeted cancer therapy.
肿瘤作为一种慢性恶性疾病,在全球约占所有死亡人数的20%,是对人类健康的头号威胁。到目前为止,大多数类型的肿瘤尚无可靠的治疗方法。由于肿瘤发生和细胞癌变的病因复杂且机制不明,它们仍然是艰巨的挑战。作为应激过程调节分子和蛋白质折叠促进剂,热休克蛋白(HSPs)在癌症发展中发挥着重要作用。大多数研究表明,HSPs是主要的抗癌药物靶点之一。HSPs不仅是细胞应激反应的调节因子,还与肿瘤的起始、进展和耐药性密切相关,因此了解HSP家族参与细胞癌变的机制是理解肿瘤发生和推动抗癌药物研发的重要组成部分。在这篇综述中,我们讨论了HSP家族关键成员(HSP70、HSP90和HSP110)参与肿瘤发生和细胞癌变过程的功能及机制,并展望了HSP家族关键成员在靶向癌症治疗中的前景。